KCC2

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024
Graviton, Epilepsy, Pharmacy technician, CCM, Research, Transcranial magnetic stimulation, DS, Neuron, Vigabatrin, LGS, Psychosis, Biomarker, Element, Ligand Pharmaceuticals, Lennox–Gastaut syndrome, Patient, Acceleration, Medicine, Status epilepticus, Dravet syndrome, ROCK2, KCC2, Hemangioma, IND, Seizure, Pharmaceutical industry

In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.

Key Points: 
  • In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
  • Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023.
  • Financial runway: Ovid anticipates its cash runway will support operations and clinical development programs into the first half of 2026.
  • Ovid also anticipates several events for its current pipeline programs and clinical results for soticlestat from Takeda in 2024.

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Retrieved on: 
Friday, December 1, 2023
Neuroprotection, Benzodiazepine, Temporal lobe epilepsy, Kainic acid, Brain, KCC2, AES, American Epilepsy Society, Seizure, PD, Annual general meeting, Epilepsy, Dentate gyrus, Patient, DSM-IV codes, Pharmaceutical industry

and Chief Medical Officer of Ovid Therapeutics.

Key Points: 
  • and Chief Medical Officer of Ovid Therapeutics.
  • “GABA-AT is a validated target in seizure reduction that has been limited in clinical use to date.
  • Title: Blocking of GABA-AT Activity by OV329 Selectively Alters Tonic and Phasic Inhibition in Dentate Gyrus Granule Cells.
  • Title: Low, Repeat Dosing of OV329 Enhances GABA-AT Inhibition in Rodent Brain: Relationship between Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects.

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, November 3, 2023
Graviton, MB, KCC2, Element, Research, ROCK2, IND, TMS, Seizure, Neuron, IV, Dravet syndrome, Ligand Pharmaceuticals, SAD, Lennox–Gastaut syndrome, Development, Epilepsy, In vivo magnetic resonance spectroscopy, MRS, Transcranial magnetic stimulation, EEG, Status epilepticus, Hemangioma, Pharmaceutical industry, Takeda, Ligand

The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.

Key Points: 
  • The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
  • General and administrative expenses were $6.8 million for the three months ended September 30, 2023, as compared to $7.6 million for the same period in 2022.
  • The decrease reflects the impact of headcount reductions conducted as part of organizational changes made in the first half of 2023.
  • Total operating expenses were $12.1 million for the three months ended September 30, 2023, as compared to $12.8 million for the same period last year.

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, August 4, 2023
Seizure, Volunteering, Epilepsy, LGS, Partnership, Joint, MB, Schizophrenia, Lennox–Gastaut syndrome, DSM-IV codes, SAD, G&A, Brain, Dravet syndrome, Research, Pain, Development, Retirement, Myenteric plexus, ROCK2, KCC2, Therapy, IND, Safety, Pharmaceutical industry, Renewable energy, Clothing, Takeda, Graviton, DRS

Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor

Key Points: 
  • Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor
    NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.
  • “In the second quarter, we accomplished a strategic milestone for Ovid.
  • In the second quarter 2023, Ovid executed several non-routine non-operating cash expenditures.
  • Second quarter expenses included severance costs following a headcount reduction that primarily impacted roles within Ovid's G&A functions in June 2023.

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Retrieved on: 
Wednesday, June 28, 2023
Columbia University, SAB, Seizure, Postdoctoral researcher, Epilepsy, GABA, Pain disorder, Meg, Corporate Affairs, Doctor of Philosophy, MB, Rockefeller University, CSO, G&A, Research, CMO, CNS, GlaxoSmithKline Pharmaceuticals, Thought, Retirement, Syneos Health, ROCK2, Hemangioma, Vertex Pharmaceuticals, KCC2, Medical device, Pharmaceutical industry, Management

“We are excited as Zhong and Manoj respectively assume research and development leadership of Ovid’s focused pipeline of potential first-in-class and best-in-class CNS programs,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • “We are excited as Zhong and Manoj respectively assume research and development leadership of Ovid’s focused pipeline of potential first-in-class and best-in-class CNS programs,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Prior to joining Ovid, Dr. Zhong served in senior leadership and scientific roles at Generation Bio, Wave Life Sciences, Vertex Pharmaceuticals, and GlaxoSmithKline Pharmaceuticals.
  • Dr. Zhong will partner closely with Dr. Manoj Malhotra who is taking on an expanded role as Chief Medical Officer.
  • In addition to deepening its bench of scientific leadership, Ovid expanded the role of Meg Alexander to the position of Chief Strategy Officer.

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, May 5, 2023
Columbia University, Seizure, LGS, Human, MB, Epilepsy, Lennox–Gastaut syndrome, American Academy, Traffic barrier, Medicine, Research, Brain, Biomarker, Dravet syndrome, DS, Cholesterol 24-hydroxylase, Investigational New Drug, Animal, Patient, ROCK2, KCC2, American Academy of Neurology, IND, Safety, Pharmaceutical industry, Cryptocurrency, Takeda, Graviton

The mechanisms in this pipeline strategically position Ovid to be a leader in rare seizure-related disorders.

Key Points: 
  • The mechanisms in this pipeline strategically position Ovid to be a leader in rare seizure-related disorders.
  • Ovid will conclude its research collaboration with Columbia University by year-end 2023 and explore business development opportunities for its non-core genetic programs produced from that research initiative.
  • Financial strategy: Ovid anticipates its cash runway should fund operations into 2025 without additional funding.
  • The decrease was due to personnel cost reductions following corporate cost-cutting efforts and a headcount reduction conducted in March 2022.

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023
MB, Traffic barrier, Lennox–Gastaut syndrome, KCC2, Dravet syndrome, LGS, Royalty, Research, Clinical trial, PDP-11, Cleveland Clinic, PDP, DSM-IV codes, Phase 3, Seizure, Cleveland, Workforce, Patient, Central nervous system, Epilepsy, Novartis, Trial of the century, Fragile X syndrome, IND, Pharmaceutical industry, Medical device, Vaccine, Takeda

To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.

Key Points: 
  • To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year.
  • In addition, Ovid is eligible to receive non-dilutive capital from Takeda, if and when soticlestat is successfully approved and marketed.
  • Business development strategy: Ovid intends to conduct disciplined business development activities with a focus on clinical stage assets and enabling technologies to complement its portfolio of anti-seizure medicines.
  • The annual decrease was a result of the above mentioned cost cutting and personnel reduction efforts undertaken in 2022.

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

Retrieved on: 
Wednesday, March 8, 2023
AstraZeneca, KCC2, Neuron, Seizure, Mortality, Data, Status epilepticus, Brain, Epilepsy, EEG, AES, Animal, Death, American Epilepsy Society, Diazepam, Annual general meeting, Chlorine, Mouse, Benzodiazepine, PTZ, Behavior, DSM-IV codes, Pharmaceutical industry, Vaccine, Cryptocurrency

The paper presents data characterizing the mechanistic target engagement of OV350 and evaluates its potential in several translatable, animal seizure models.

Key Points: 
  • The paper presents data characterizing the mechanistic target engagement of OV350 and evaluates its potential in several translatable, animal seizure models.
  • Several mechanistic studies articulated in Cell Reports Medicine suggest that OV350:
    Directly binds to the KCC2 co-transporter with high affinity and potentiates KCC2 activity without modifying its plasma membrane accumulation or key regulatory phosphorylation sites.
  • In this model, mice were administered kainate, a convulsant that induces status epilepticus-like seizures, which are typically resistant to benzodiazepines.
  • Findings from some of the published models were previously presented at the American Epilepsy Society (AES) Annual Meeting in December 2022, and published in Cell Reports Medicine publication in February 2023.

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Retrieved on: 
Wednesday, February 8, 2023
Seizure, Research, Kaiser Permanente, Lennox–Gastaut syndrome, Cholesterol 24-hydroxylase, Epilepsy Research UK, Takeda Pharmaceutical Company, Neurophysiology, Epilepsy, Multiple sclerosis, MB, Head, Neurology, Cleveland Clinic, Cleveland, Drug discovery, KCC2, Growth, Takeda, Therapy, Pharmaceutical industry

Dr. Malhotra brings to Ovid deep expertise from his career serving as a clinical trialist, a treating epileptologist, and a senior medical affairs executive within biopharmaceutical companies.

Key Points: 
  • Dr. Malhotra brings to Ovid deep expertise from his career serving as a clinical trialist, a treating epileptologist, and a senior medical affairs executive within biopharmaceutical companies.
  • He joins us from senior roles at global pharmaceutical companies where he contributed to the development and approval of multiple neurological medicines,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.
  • He joins Ovid from Takeda Pharmaceuticals, where he played a critical role in the invention and development of soticlestat, a small molecule inhibitor of cholesterol 24-hydroxylase.
  • At Ovid, he will support preclinical development, including a dedicated focus on the KCC2 program.

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Retrieved on: 
Friday, December 2, 2022
Takeda Pharmaceutical Company, Lennox–Gastaut syndrome, Epilepsy, COVID-19, Safety, Vigabatrin, Seizure, Brain, Dravet syndrome, KCC2, Therapy, Benzodiazepine, CKM, MES, American Epilepsy Society, Security (finance), Annual general meeting, AES, Risk, Temporal lobe epilepsy, MB, Pharmaceutical industry, Takeda

If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Our pipeline of potential medicines is designed with unique mechanisms of action to address the diverse, underlying pathophysiology of seizures.
  • Our data suggest OV329 to be a potent, next-generation GABA-AT inhibitor with the potential for seizure reduction with chronic, low dosing.
  • Data presented on OV350 support the therapeutic opportunity associated with activating KCC2, a novel target in epilepsy.